All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
The vector of anti-DLL3 chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human DLL3. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-DLL3 antibody linked to 41BB and CD3ζ signaling domains. And the vector product was designed for the treatment of Lung malignancy.
CAR Construction : Fig.1 T cell binding analysis of the SC16.15. Binding properties of the delta-like 3 (DLL3) bispecific antibody. Chen, X., Amar, N., Zhu, Y., Wang, C., Xia, C., Yang, X., ... & Feng, M. (2020). Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth. Journal for immunotherapy of cancer, 8(1). |
CAR Construction : Fig.2 PD-L1 expression on H446 and A431 (DLL3) cells. One million of cells was stained with PD-L1 rabbit monoclonal antibody, followed by detection with APC-conjugated goatanti-rabbit IgG. Chen, X., Amar, N., Zhu, Y., Wang, C., Xia, C., Yang, X., ... & Feng, M. (2020). Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth. Journal for immunotherapy of cancer, 8(1). |
CAR Construction : Fig.3 In vitro cell killing assay of the delta-like 3 (DLL3)-targeted chimeric antigen receptor (CAR)-T. Transduction efficiency analysis of the CAR-T cells, as indicated by the expression of mScarlet-I. Untransduced PBMC was used as negative control. Chen, X., Amar, N., Zhu, Y., Wang, C., Xia, C., Yang, X., ... & Feng, M. (2020). Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth. Journal for immunotherapy of cancer, 8(1). |
CAR Construction : Fig.4 PD-1 expression on CAR-T cells. DLL3 CAR-T cells (red curve) and HN3 control CAR-T cells (blue curve) were stained with the PD-1 inhibitory antibody (in-house made scFv-hFc format), followed by APC-conjugated goat-anti-human IgG. Chen, X., Amar, N., Zhu, Y., Wang, C., Xia, C., Yang, X., ... & Feng, M. (2020). Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth. Journal for immunotherapy of cancer, 8(1). |
CAR Construction : Fig.5 In vivo efficacy testing of the delta-like 3 (DLL3)-targeted chimeric antigen receptor (CAR)-T cells. The survival curves of the treated mice. Chen, X., Amar, N., Zhu, Y., Wang, C., Xia, C., Yang, X., ... & Feng, M. (2020). Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth. Journal for immunotherapy of cancer, 8(1). |
More Published Data More Published Data
There are currently no customer reviews or questions for Anti-DLL3 (hSC16.15) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-ZP131). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION